[{"id":"ad6effdc-77e6-48b7-93c9-786714c4d278","acronym":"EXCEED ET","url":"https://clinicaltrials.gov/study/NCT05482971","created_at":"2023-07-03T18:10:07.965Z","updated_at":"2024-07-02T16:35:34.897Z","phase":"Phase 2","brief_title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","source_id_and_acronym":"NCT05482971 - EXCEED ET","lead_sponsor":"PharmaEssentia","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/29/2022","start_date":" 09/29/2022","primary_txt":" Primary completion: 07/29/2024","primary_completion_date":" 07/29/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-03"},{"id":"23e94fe6-5db5-4814-8780-12a2c9a9dde5","acronym":"ENDURE-CML-IX","url":"https://clinicaltrials.gov/study/NCT03117816","created_at":"2021-04-28T11:52:33.963Z","updated_at":"2024-07-02T16:35:51.664Z","phase":"Phase 3","brief_title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","source_id_and_acronym":"NCT03117816 - ENDURE-CML-IX","lead_sponsor":"Philipps University Marburg Medical Center","biomarkers":" ABL1 • BCR • PD-1 • IL6 • IL10 • CD86","pipe":"","alterations":" ","tags":["ABL1 • BCR • PD-1 • IL6 • IL10 • CD86"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Completed","enrollment":" Enrollment 214","initiation":"Initiation: 05/04/2017","start_date":" 05/04/2017","primary_txt":" Primary completion: 01/26/2022","primary_completion_date":" 01/26/2022","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2023-03-31"},{"id":"b2a99631-d050-4b24-a01c-610e13438bd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01933906","created_at":"2022-04-24T08:56:26.993Z","updated_at":"2024-07-02T16:37:04.233Z","phase":"Phase 1","brief_title":"Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response","source_id_and_acronym":"NCT01933906","lead_sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • Besremi (ropeginterferon alfa-2b-njft)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 08/30/2013","start_date":" 08/30/2013","primary_txt":" Primary completion: 11/14/2018","primary_completion_date":" 11/14/2018","study_txt":" Completion: 11/14/2018","study_completion_date":" 11/14/2018","last_update_posted":"2019-01-04"}]